Speaker: Jay M. Young, MD, Medical Director, South Orange County Medical Research Center, Laguna Woods, California.
Patients with overactive bladder who received extended-release (ER) tolterodine tartrate (Detrol drug LA, Pharmacia) experienced significantly improved perceptions of urinary urgency and bladder condition, compared with patients who took placebo.

Speaker: William G. Moseley, MD, Medical Director, San Diego Uro-Research, San Diego, California.
Vardenafil (Levitra drug, Bayer/GlaxoSmithKline), a new anti-impotence agent, provided clinically significant, sustained improvement in erectile function over a two-year period in men with erectile dysfunction (ED), whether or not they had previously used the original anti-impotence drug sildenafil (Viagra®, Pfizer).

Speaker: Craig Zippe, MD, Staff Surgeon, Section of Urologic Oncology, and Co-Director, Prostate Center and Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function, The Cleveland Clinic, Cleveland, Ohio.
The early use of an alprostadil urethral suppository (Muse®, Vivus, Inc.) in men following bilateral nerve-sparing radical prostatectomy appears to facilitate a rapid return to [...]

Long-Acting LH-RH Agonist Depot (Leuprolide Acetate) for Prostate Cancer
Speaker: Robert C. Tyler, MD, Director of Clinical Research, Atrix Laboratories, Inc., Fort Collins, Colorado.
A new six-month subcutaneous (SC) depot of leuprolide acetate (Eligard®, Atrix Laboratories, Inc.), a synthetic luteinizing hormone-releasing hormone (LH-RH) agonist, consistently produced and maintained safe and effective serum testosterone suppression. Total serum testosterone [...]